About Us
Abiosciences is the US headquarters of Analytical Biosciences, a single cell genomics company focusing on accelerating the development of novel therapeutics. Its mission is to unlock the mechanism of diseases through the most advanced translational single cell platforms with the largest, high-resolution databases, and the most comprehensive commercial grade data analytics. Led by science and data, the company has been and will continue to generate new knowledge and compile/organize insights for the identification and validation of novel cellular targets and biomarkers, which ultimately lead to next generation breakthrough therapeutics and diagnostics.
News
Breaking news and amazing progress in science and development of Abiosciences.
Analytical Biosciences Named Finalist in IDC’s Inaugural Best in Future of Digital Infrastructure North America Awards
Analytical Biosciences and MemVerge implement world’s first Big Memory Computing environment for genomics research to fight cancer and stop the spread of COVID-19
Read moreNew Product | OmniAnalyzer®, A One-stop Single-Cell Data Analysis Software
On September 2nd, 2021, Analytical BioSciences releases a one-stop single-cell data analysis software, OmniAnalyzer®. OmniAnalyzer® is a standalone software for single cell multi-omics data analysis on code-free interface, enabling interactive data visualizations and generating publishable results.
Read moreAnalytical BioScience Reached Commercial Agreement with Human Cell Atlas
We are happy to announce that we have reached a commercial agreement with the Human Cell Atlas (HCA) to help empower science discoveries of HCA collaborating members by providing #SingleCell sequencing and data analysis solutions, software and platform at a favorable price.
Read moreAnalytical BioSciences Closes Series A4 Financing Led by Sequoia Capital China to Accelerate Single-cell Genomics & AI Based Cancer Therapeutics and Diagnostics
May 25 2021, Analytical BioSciences Ltd. (Abio), a leader in single cell genomics, today announced the successful completion of Series A4 financing. Sequoia Capital China led this round of investment, and was joined by Green Pine Capital Partners and Primavera Venture Partners. IDG Capital, the original founding investor for Analytical Biosciences, also participated in this financing round.
Read more
